Enhancing the action of serotonin by three different mechanisms prevents spontaneous seizure‐induced mortality in Dravet mice

Abstract

AbstractObjectiveSudden unexpected death in epilepsy (SUDEP) is an underestimated complication of epilepsy. Previous studies have demonstrated that enhancement of serotonergic neurotransmission suppresses seizure‐induced sudden death in evoked seizure models. However, it is unclear whether elevated serotonin (5‐HT) function will prevent spontaneous seizure‐induced mortality (SSIM), which is characteristic of human SUDEP. We examined the effects of 5‐HT‐enhancing agents that act by three different pharmacological mechanisms on SSIM in Dravet mice, which exhibit a high incidence of SUDEP, modeling human Dravet syndrome.MethodsDravet mice of both sexes were evaluated for spontaneous seizure characterization and changes in SSIM incidence induced by agents that enhance 5‐HT‐mediated neurotransmission. Fluoxetine (a selective 5‐HT reuptake inhibitor), fenfluramine (a 5‐HT releaser and agonist), SR 57227 (a specific 5‐HT3 receptor agonist), or saline (vehicle) was intraperitoneally administered over an 8‐day period in Dravet mice, and the effect of these treatments on SSIM was examined.ResultsSpontaneous seizures in Dravet mice generally progressed from wild running to tonic seizures with or without SSIM. Fluoxetine at 30 mg/kg, but not at 20 or 5 mg/kg, significantly reduced SSIM compared with the vehicle control. Fenfluramine at 1–10 mg/kg, but not .2 mg/kg, fully protected Dravet mice from SSIM, with all mice surviving. Compared with the vehicle control, SR 57227 at 20 mg/kg, but not at 10 or 5 mg/kg, significantly lowered SSIM. The effect of these drugs on SSIM was independent of sex.SignificanceOur data demonstrate that elevating serotonergic function by fluoxetine, fenfluramine, or SR 57227 significantly reduces or eliminates SSIM in Dravet mice in a sex‐independent manner. These findings suggest that deficits in serotonergic neurotransmission likely play an important role in the pathogenesis of SSIM, and fluoxetine and fenfluramine, which are US Food and Drug Administration‐approved medications, may potentially prevent SUDEP in at‐risk patients.